Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

The efficacy of salvage autologous stem cell transplant among patients with multiple myeloma who received maintenance therapy post initial transplant

Bone Marrow Transplantation volume 53, pages 1483–1486 (2018)Cite this article

Subjects

Autologous stem cell transplant (ASCT) remains a standard of care for patients with multiple myeloma (MM) even in the era of novel drugs. However, MM remains incurable and most patients relapse after ASCT. A second ASCT is one of the treatment options for these patients with relapsed MM that offers additional progression-free survival (PFS) and overall survival (OS) advantage over conventional chemotherapy [1, 2].

Studies conducted in an era before the routine use of maintenance therapy post-ASCT have shown PFS to be about 40–50% of what is achieved after a first ASCT [3]. However, there is a lack of data on survival outcomes after 2nd ASCT in the era of modern maintenance therapy. Here, we report outcomes of patients undergoing 2nd ASCT who received maintenance therapy after the initial ASCT in comparison with a cohort who did not receive maintenance.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, et al. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol. 2016;3:e340–51. https://doi.org/10.1016/S2352-3026(16)30049-7.

    Article  PubMed  Google Scholar 

  2. Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA, et al. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:874–85. https://doi.org/10.1016/S1470-2045(14)70245-1.

    Article  CAS  PubMed  Google Scholar 

  3. Atanackovic D, Schilling G. Second autologous transplant as salvage therapy in multiple myeloma. Br J Haematol. 2013;163:565–72. https://doi.org/10.1111/bjh.12579.

    Article  PubMed  Google Scholar 

  4. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20. https://doi.org/10.1200/JCO.2005.04.242.

    Article  PubMed  Google Scholar 

  5. Vincent Rajkumar S. Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89:999–1009. https://doi.org/10.1002/ajh.23810.

    Article  CAS  PubMed  Google Scholar 

  6. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–73. https://doi.org/10.1038/sj.leu.2404284.

    Article  CAS  PubMed  Google Scholar 

  7. Singh Abbi KK, Zheng J, Devlin SM, Giralt S, Landau H. Second autologous stem cell transplant: an effective therapy for relapsed multiple myeloma. Biol Blood Marrow Transplant. 2015;21:468–72. https://doi.org/10.1016/j.bbmt.2014.11.677.

    Article  PubMed  Google Scholar 

  8. Shah N, Ahmed F, Bashir Q, Qureshi S, Dinh Y, Rondon G, et al. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer. 2012;118:3549–55. https://doi.org/10.1002/cncr.26662.

    Article  PubMed  Google Scholar 

  9. Grovdal M, Nahi H, Gahrton G, Liwing J, Waage A, Abildgaard N, et al. Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT. Bone Marrow Transplant. 2015;50:808–12. https://doi.org/10.1038/bmt.2015.39.

    Article  CAS  PubMed  Google Scholar 

  10. Jimenez-Zepeda VH, Mikhael J, Winter A, Franke N, Masih-Khan E, Trudel S, et al. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant. 2012;18:773–9. https://doi.org/10.1016/j.bbmt.2011.10.044.

    Article  PubMed  Google Scholar 

  11. Gonsalves WI, Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, et al. Second auto-SCT for treatment of relapsed multiple myeloma. Bone Marrow Transplant. 2013;48:568–73. https://doi.org/10.1038/bmt.2012.183.

    Article  CAS  PubMed  Google Scholar 

  12. Sellner L, Heiss C, Benner A, Raab MS, Hillengass J, Hose D, et al. Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients. Cancer. 2013;119:2438–46. https://doi.org/10.1002/cncr.28104.

    Article  CAS  PubMed  Google Scholar 

  13. Gimsing P, Hjertner O, Abildgaard N, Andersen NF, Dahl TG, Gregersen H, et al. Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial. Bone Marrow Transplant. 2015;50:1306–11. https://doi.org/10.1038/bmt.2015.125.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, et al. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transplant. 2015;21:2039–51. https://doi.org/10.1016/j.bbmt.2015.09.016.

    Article  PubMed  PubMed Central  Google Scholar 

  15. McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hospital Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA

    Shivaprasad Manjappa

  2. Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA

    Mark A. Fiala, Justin King, Daniel A. Kohnen & Ravi Vij

Authors
  1. Shivaprasad Manjappa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark A. Fiala
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Justin King
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniel A. Kohnen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ravi Vij
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ravi Vij.

Ethics declarations

Conflict of interest

RV: Bristol-Myers Squibb: Consultancy and Research Support; Takeda: Consultancy and Research Support; Amgen: Consultancy and Research Support; Celgene: Consultancy and Research Support; Janssen: Consultancy; Novartis: Consultancy; Jazz: Consultancy; Karyopharma: Consultancy. The remaining authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Manjappa, S., Fiala, M.A., King, J. et al. The efficacy of salvage autologous stem cell transplant among patients with multiple myeloma who received maintenance therapy post initial transplant. Bone Marrow Transplant 53, 1483–1486 (2018). https://doi.org/10.1038/s41409-018-0216-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-018-0216-3

This article is cited by

Search

Advanced search

Quick links